The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ESPR | +30.73% | -91.71% | -39.2% | -81% |
| S&P | +16.23% | +94.45% | +14.22% | +320% |
Esperion Therapeutics, Inc. is a pharmaceutical company. It engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
Shareholders were displeased with the company's latest financial move.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $82.39M | 11.6% |
| Gross Profit | $53.84M | -7.5% |
| Gross Margin | 65.35% | -13.5% |
| Market Cap | $195.11M | -48.4% |
| Market Cap / Employee | $0.64M | 0.0% |
| Employees | 304 | 26.7% |
| Net Income | -$12.73M | 79.5% |
| EBITDA | $7.12M | 175.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $86.06M | -54.5% |
| Accounts Receivable | $107.75M | 78.5% |
| Inventory | 114.5 | 35.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $474.36M | -9.0% |
| Short Term Debt | $123.82M | 249.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -29.75% | 3.8% |
| Return On Invested Capital | -153.68% | 2.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$23.92M | -228.5% |
| Operating Free Cash Flow | -$23.92M | -232.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -0.93 | -1.16 | -0.73 | -0.45 | -67.95% |
| Price to Sales | 1.09 | 1.29 | 1.09 | 0.73 | -51.93% |
| Price to Tangible Book Value | -0.93 | -1.16 | -0.73 | -0.45 | -67.94% |
| Enterprise Value to EBITDA | -46.03 | -199.57 | -34.52 | 99.21 | -67.34% |
| Total Debt | $559.59M | $591.21M | $594.00M | $598.18M | 7.46% |
ESPR earnings call for the period ending June 30, 2022.
ESPR earnings call for the period ending March 31, 2022.
ESPR earnings call for the period ending December 31, 2021.
ESPR earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
